Inovio Pharmaceuticals, Inc. $INO Shares Sold by Two Seas Capital LP

Two Seas Capital LP lessened its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 26.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,479,493 shares of the biopharmaceutical company’s stock after selling 1,267,017 shares during the period. Inovio Pharmaceuticals accounts for approximately 2.8% of Two Seas Capital LP’s portfolio, making the stock its 6th biggest position. Two Seas Capital LP owned about 4.23% of Inovio Pharmaceuticals worth $142,764,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Focus Partners Wealth purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at about $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the period. Raymond James Financial Inc. raised its stake in Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 16,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Inovio Pharmaceuticals in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

NASDAQ INO opened at $1.18 on Friday. The stock has a market capitalization of $122.01 million, a P/E ratio of -1.30 and a beta of 1.52. The firm’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.29. Inovio Pharmaceuticals, Inc. has a 12 month low of $0.56 and a 12 month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. As a group, analysts anticipate that Inovio Pharmaceuticals, Inc. will post -0.72 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on INO. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, August 13th. Jefferies Financial Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and upped their price objective for the company from $1.80 to $3.00 in a report on Thursday, August 13th. Weiss Ratings lowered Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $3.17.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.